Nateghi B, Shams E, Behshood P, Fathullahzadeh S, Salehi M. Expression Profiles of miR-93 and miR-330 in Iranian Patients with Chronic Lymphocytic Leukemia. IJML 2019; 6 (2) :100-106
URL:
http://ijml.ssu.ac.ir/article-1-256-en.html
Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract: (2740 Views)
Background and Aims: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Research has shown that in CLL, microRNAs can have function as oncogenes or tumor suppressors. Some studies demonstrated that the expression of microRNA-93 (miR-93) and microRNA-330 (miR-330) have been changed in several cancers, including lung, prostate, and colon cancer. We aimed to elucidate the changes in miR-93 and miR-330 expression in CLL patients in comparison with controls.
Materials and Methods: In this case-control study, the expression levels of miR-93 and miR-330 was evaluated in 30 CLL patients who had referred to Omid Hospital, Isfahan, Iran, and 30 controls in peripheral blood mononuclear cells using reverse transcription quantitative PCR (RT-qPCR).
Results: The expression of miR-93 and miR-330 were found to significantly increase in CLL patients compared with controls (p<0.0001).
Conclusions: The findings indicated that miR-93 and miR-330 are probably the novel potential biomarker for early diagnosis of CLL, at least in Iranian patients. However, for a decisive result, further investigations are warranted.
Type of Study:
Research |
Subject:
Genetics/ Biotechnology Received: 2018/09/1 | Accepted: 2019/05/11 | Published: 2019/05/31